ARTIVION, INC.
No SEC Form 4 filings for $AORT in the last 30 days.
Artivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.
ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aort-2026x8k063026ex991.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Ph
Artivion (NYSE: AORT) will report earnings Thursday after the bell. Last quarter it posted revenue of $116.3M, up 17.5% YoY, but missed analysts’ EPS and slightly missed full-year revenue guidance. This quarter consensus calls for 6.7% YoY revenue growth. Analysts’ estimates were largely unchanged; average price target is $42 vs $27.30.
Over the past 7 days, alphai's AI scored 3 news stories mentioning AORT (ARTIVION, INC.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent AORT coverage spans financial news, earnings and insider activity.
The article provides a fresh earnings datapoint (revenue and EPS beat) plus full-year revenue and EPS expectations, which can drive near-term positioning.
FDA PMA approval for the AMDS Hybrid Prosthesis and Endospan acquisition completion add near-term execution credibility, while guidance reiteration frames expectations for 2026 margins and growth.
Earnings are the primary catalyst, with sentiment skewed by prior revenue estimate misses and a slightly below-consensus full-year revenue outlook.
The article flags a demand softness issue in Artivion’s AMDS starter set sales that drove a full-year outlook reduction.
U.S. commercialization start for a high-acuity device can drive incremental revenue and improve product pipeline credibility.
alphai scores every news story that mentions AORT with an AI model for sentiment and relevance, and aggregates insider trades from ARTIVION, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.
4 min readARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aort-2026x8k063026ex991.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Ph
7 min readArtivion (NYSE: AORT) will report earnings Thursday after the bell. Last quarter it posted revenue of $116.3M, up 17.5% YoY, but missed analysts’ EPS and slightly missed full-year revenue guidance. This quarter consensus calls for 6.7% YoY revenue growth. Analysts’ estimates were largely unchanged; average price target is $42 vs $27.30.
3 min readIn its Q2 2026 investor letter, Alger Weatherbie Specialized Growth Fund cited Artivion, Inc. (NYSE:AORT) after the company reported in-line Q1 results but modestly lowered its full-year outlook. The update attributed the change to slower-than-expected starter set sales for AMDS. AORT closed July 20, 2026 at $25.37, with a $1.23B market cap.
4 min readBiotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min readGREEN ANDREW M (SVP, Regulatory and Quality) sold 44,001 shares of ARTIVION, INC. (AORT) at an average of $20.70 ($20.69–$20.71, $0.91M total) across 2 trades on 2026-06-11 under a Rule 10b5-1 trading plan.
1 min readArtivion (AORT) Director Marna P. Borgstrom has received an equity compensation grant of 7,850 shares of Common Stock at a stated price of $0.00 per share, as reported in a Form 4 SEC filing. This award, part of the company's Equity and Cash Incentive Plan, increases her direct holdings to 56,938 shares. The RSA grant is scheduled to vest on May 14, 2027, aligning director compensation with the company's long-term performance.
2 min readJuniper Investment Company LLC significantly reduced its stake in Artivion, Inc. (NYSE:AORT) by 36.3%, selling 760,257 shares and now owning 1,333,692 shares valued at $56.47 million. Despite insider selling and a high P/E ratio, other institutional investors like Vanguard and Two Sigma increased their holdings, and analysts maintain a "Moderate Buy" rating with an average target price of $50.47. Artivion recently exceeded earnings and revenue expectations.
3 min readArtivion Inc.'s stock (AORT) reached an all-time high of $48.06, driven by strong investor confidence and impressive financial performance, including a 58.86% one-year return and a recent beat on Q3 2025 earnings. Analysts maintain optimistic outlooks with raised price targets, reflecting confidence in the company's future prospects and upcoming product launches.
3 min readHere is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.
3 min read
